The Bill 118 hr 133, also known as the Mandating Exclusive Review of Individual Treatments (MERIT) Act, aims to establish a new process for the review of individual medical treatments by the Centers for Medicare and Medicaid Services (CMS). The bill proposes that CMS must conduct an exclusive review of any new medical treatment or service that is not covered by Medicare or Medicaid before it can be approved for coverage.
Under the MERIT Act, healthcare providers would be required to submit detailed information about the treatment, including its effectiveness, safety, and cost, to CMS for review. CMS would then have 90 days to conduct a thorough evaluation of the treatment and determine whether it meets the necessary criteria for coverage under Medicare and Medicaid.
The goal of the MERIT Act is to ensure that only high-quality, evidence-based treatments are covered by Medicare and Medicaid, while also promoting transparency and accountability in the healthcare system. Proponents of the bill argue that it will help to reduce unnecessary spending on ineffective treatments and improve patient outcomes.
Critics of the MERIT Act, however, raise concerns about potential delays in access to new treatments for patients, as well as the administrative burden it may place on healthcare providers. They also question whether CMS has the resources and expertise necessary to conduct timely and thorough reviews of individual treatments.
Overall, the MERIT Act represents a significant change in the way that new medical treatments are evaluated for coverage under Medicare and Medicaid. Its impact on patients, healthcare providers, and the healthcare system as a whole remains to be seen.